Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS

Quantum Biopharma ( (TSE:QNTM) ) has issued an update.

Quantum BioPharma Ltd., a Toronto-based biopharma developer of treatments for neurodegenerative and metabolic diseases and alcohol misuse, is advancing its lead multiple sclerosis candidate Lucid-MS, a patented new chemical entity aimed at preventing and reversing myelin degradation. The company also holds a minority economic interest and royalty stream in the Unbuzzd OTC brand and maintains a portfolio of secured loans and a sizeable tax loss carryforward that could support future profitability.

On March 30, 2026, Quantum BioPharma signed a binding letter of intent with global contract research organization Allucent to run a Phase 2 clinical trial of Lucid-MS in multiple sclerosis patients. The alliance, ahead of an expected second-quarter 2026 trial start pending regulatory clearance and a final services agreement, is set to provide end-to-end clinical and regulatory support and could strengthen Quantum BioPharma’s position in the fast-growing, roughly $38 billion MS market by pursuing a differentiated, neuroprotective mechanism targeting demyelination rather than immune modulation.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders as well as alcohol misuse. Through subsidiary Lucid Psycheceuticals, its lead compound Lucid-MS targets myelin degradation in multiple sclerosis, while it also benefits from royalty-linked exposure to OTC alcohol misuse product Unbuzzd and a C$130 million tax loss carryforward.

YTD Price Performance: -37.43%

Average Trading Volume: 12,218

Technical Sentiment Signal: Sell

Current Market Cap: C$27.05M

For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.